NervGen Pharma (NGEN) Stock Price, News & Analysis

Company Overview

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies designed to promote nervous system repair and functional recovery after injury or disease. The company is headquartered in Vancouver, British Columbia, and is listed on the Nasdaq Capital Market and the TSX Venture Exchange under the symbol NGEN.

NervGen’s lead product candidate is NVG-291, an investigational peptide intended to enhance the body’s natural capacity for neural repair by modulating the protein tyrosine phosphatase sigma receptor. The company is evaluating NVG-291 in conditions involving damage to the central or peripheral nervous system, including spinal cord injury and multiple sclerosis.

NervGen’s development programs are centered on advancing regenerative medicines through clinical testing, with the goal of addressing neurological impairments for which existing treatment options are limited. The company’s research builds on preclinical work suggesting that its approach may help restore connections between nerve cells and improve recovery following nervous system damage.

Key Stats

• Today's Range: $1.42 to $1.55
• 50-Day Range: $1.42 to $2.34
• 52-Week Range: $1.37 to $6.30
• Volume: 539,410 shs
• Average Volume: N/A
• Market Capitalization: $119.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Moderate Buy

NervGen Pharma Stock Analysis - MarketRank™

NervGen Pharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 499th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NervGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NervGen Pharma has a consensus price target of $14.00, representing about 845.9% upside from its current price of $1.48.

Amount of Analyst Coverage

NervGen Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NervGen Pharma are expected to grow in the coming year, from ($0.55) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NervGen Pharma is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NervGen Pharma is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.31% of the float of NervGen Pharma has been sold short.

Short Interest Ratio / Days to Cover

NervGen Pharma has a short interest ratio ("days to cover") of 10.21, which indicates bearish sentiment.

Change versus previous month

Short interest in NervGen Pharma has recently decreased by 12.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NervGen Pharma does not currently pay a dividend.

Dividend Growth

NervGen Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.95

News Sentiment

NervGen Pharma has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for NervGen Pharma this week, compared to 3 articles on an average week.

MarketBeat Follows

9 people have added NervGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NervGen Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

NervGen Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NGEN
• CIK: 1751912
• Web: nervgen.com
• Phone: (604) 722-5361
• Fax: N/A
• Employees: 8
• Year Founded: 2017

Price Target and Rating

• Average Price Target for NervGen Pharma: $14.00
• High Price Target: $18.00
• Low Price Target: $10.00
• Potential Upside/Downside: +845.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 80,631,000
• Free Float: N/A
• Market Cap: $119.33 million
• Optionable: Optionable
• Beta: N/A